前沿生物技术药物的发展趋势与战略图谱

Development trends and strategic landscape of cutting-edge biopharmaceuticals

摘要

围绕抗体药物、 多肽药物、 细胞治疗、基因治疗与核酸药物五大前沿生物技术药物, 从发展脉络、 核心突破、 驱动力量三大维度, 系统阐述各领域从靶点发现到临床转化的关键里程碑。 在此基础上, 以 “瓶颈-突破-展望-保障” 为递进链条, 绘制一幅兼具学术前瞻、 产业发展与政策导向的战略图谱。 五大前沿生物技术药物作用机制各异, 但受限于递送效率、 生产规模和临床转化三大瓶颈; 突破路径集中在智能设计、 递送创新和平台融合三个方向。 五大技术共同推动药物从静态靶向至动态响应跨越, 呈现出更智能、 更可控、 更精准的未来趋势。 从技术创新、 国际合作与政策支持三个角度, 提出完善中国生物医药创新生态的具体建议。 为生物技术药物前沿探索提供理论支撑, 也为产业规划与政策制定提供参考。

Abstract

Focusing on five cutting-edge biopharmaceuticals-antibody drugs, peptide drugs, cell therapy, gene therapy, and nucleic acid drugs-this study systematically illustrates the key milestones from target discovery to clinical translation across three dimensions: development history, core breakthroughs, and driving forces. Building on this analysis, we map out a strategic landscape that integrates academic foresight, industrial development, and policy orientation using the progressive framework of “bottleneck-breakthrough-prospect-support”. Despite their distinct mechanisms, these five frontier biopharmaceuticals face three major bottlenecks, including delivery efficiency, production scale, and clinical translation. Addressing these challenges converges on three strategic pathways: intelligent design, delivery innovation, and platform integration. Collectively, these five technologies are driving the evolution of pharmaceuticals from static targeting to dynamic responsiveness, making therapeutics smarter, more precise, and more controllable. From the perspectives of technological innovation, international collaboration, and policy support, we propose concrete steps to strengthen China's biomedical innovation ecosystem. This study provides theoretical support for frontier exploration in biopharmaceuticals and offers a reference for industrial planning and policy formulation.

关键词

生物技术药物 / 抗体药物 / 多肽药物 / 细胞治疗 / 基因治疗 / 核酸药物 / 药物设计 / 药物评价

Key words

biopharmaceuticals / antibody drugs / peptide drugs / cell therapy / gene therapy / nucleic acid drugs / drug design / drug evaluation

参考文献

[1] ASHFORD M, BAK A. Delivery science: its increasing importance for the next generation of medicines[J]. J Control Release, 2026, 392: 114663. DOI: 10.1016/j.jconrel.2026.114663.

[2] CHAN A C, MARTYN G D, CARTER P J. Fifty years of monoclonals: the past, present and future of antibody therapeutics[J]. Nat Rev Immunol, 2025, 25(10): 745-765. DOI: 10.1038/s41577-025-01207-9.

[3] KÖHLER G, MILSTEIN C. Continuous cultures of fused cells secreting antibody of predefined specificity[J]. Nature, 1975, 256(5517): 495-497. DOI: 10.1038/256495a0.

[4] MCLAUGHLIN P, GRILLO-LÓPEZ A J, LINK B K, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program[J]. J Clin Oncol, 2023, 41(2): 154-162. DOI: 10.1200/JCO.22.02403.

[5] SLAMON D J, LEYLAND-JONES B, SHAK S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J]. N Engl J Med, 2001, 344(11): 783-792. DOI: 10.1056/NEJM200103153441101.

[6] BACA M, PRESTA L G, O'CONNOR S J, et al. Antibody humanization using monovalent phage display[J]. J Biol Chem, 1997, 272(16): 10678-10684. DOI: 10.1074/jbc.272.16.10678.

[7] JAKOBOVITS A, AMADO R G, YANG X D, et al. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice[J]. Nat Biotechnol, 2007, 25(10): 1134-1143. DOI: 10.1038/nbt1337.

[8] WARD E S, GÜSSOW D, GRIFFITHS A D, et al. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli[J]. Nature, 1989, 341(6242): 544-546. DOI: 10.1038/341544a0.

[9] GAO X Y, XU N, LI Z Y, et al. Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial[J]. Lancet Oncol, 2023, 24(10): 1134-1146. DOI: 10.1016/S1470-2045(23)00411-4.

[10] NAING A, THISTLETHWAITE F, DE VRIES E G E, et al. CX-072 (pacmilimab), a Probody® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study[J]. J Immunother Cancer, 2021, 9(7): e002447. DOI: 10.1136/jitc-2021-002447.

[11] ABRAMSON A, FREDERIKSEN M R, VEGGE A, et al. Oral delivery of systemic monoclonal antibodies, peptides and small molecules using gastric auto-injectors[J]. Nat Biotechnol, 2022, 40(1): 103-109. DOI: 10.1038/s41587-021-01024-0.

[12] OTA N, DAVIES C W, KANG J, et al. Engineering a protease-stable, oral single-domain antibody to inhibit IL-23 signaling[J]. Proc Natl Acad Sci U S A, 2025, 122(22): e2501635122. DOI: 10.1073/pnas.2501635122.

[13] BERGER S, SEEGER F, YU T Y, et al. Preclinical proof of principle for orally delivered Th17 antagonist miniproteins[J]. Cell, 2024, 187(16): 4305-4317.e18. DOI: 10.1016/j.cell.2024.05.052.

[14] ASTRUP A, RÖSSNER S, VAN GAAL L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study[J]. Lancet, 2009, 374(9701): 1606-1616. DOI: 10.1016/s0140-6736(09)61375-1.

[15] WILDING J P H, BATTERHAM R L, CALANNA S, et al. Once-weekly semaglutide in adults with overweight or obesity[J]. N Engl J Med, 2021, 384(11): 989-1002. DOI: 10.1056/nejmoa2032183.

[16] FRÍAS J P, DAVIES M J, ROSENSTOCK J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes[J]. N Engl J Med, 2021, 385(6): 503-515. DOI: 10.1056/nejmoa2107519.

[17] JI L N, JIANG H W, BI Y, et al. Once-weekly mazdutide in Chinese adults with obesity or overweight[J]. N Engl J Med, 2025, 392(22): 2215-2225. DOI: 10.1056/nejmoa2411528.

[18] SON J W, LE ROUX C W, BLÜHER M, et al. Novel GLP-1-based medications for type 2 diabetes and obesity[J]. Endocr Rev, 2026, 47(2): 159-177. DOI: 10.1210/endrev/bnaf036.

[19] BUCKLEY S T, BæKDAL T A, VEGGE A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist[J]. Sci Transl Med, 2018, 10(467): eaar7047. DOI: 10.1126/scitranslmed.aar7047.

[20] BOUZIANAS D, BOUZIANA S. First pediatric B-acute lymphoblastic leukemia patient treated with anti-CD19 chimeric antigen receptor T-cell therapy: long-term remission or early cure?[J]. Hum Vaccines Immunother, 2024, 20: 2321678. DOI: 10.1080/21645515.2024.2321678.

[21] ZHU P, LI S Y, DING J, et al. Combination immunotherapy of glioblastoma with dendritic cell cancer vaccines, anti-PD-1 and poly I:C[J]. J Pharm Anal, 2023, 13(6): 616-624. DOI: 10.1016/j.jpha.2023.04.012.

[22] HANINA S A, PARK T, LOPEZ M, et al. Sensitive CAR T cells redefine targetable CD70 expression in solid tumors[J]. Science, 2026, 391(6788): 896-905. DOI: 10.1126/science.adv7378.

[23] MANSILLA-SOTO J, EYQUEM J, HAUBNER S, et al. HLA-independent T cell receptors for targeting tumors with low antigen density[J]. Nat Med, 2022, 28(2): 345-352. DOI: 10.1038/s41591-021-01621-1.

[24] ROSENBERG S A. Lymphocytes as a living drug for cancer[J]. Science, 2024, 385(6704): 25-26. DOI: 10.1126/science.adp1130.

[25] SPANIER J A, FUNG V, WARDELL C M, et al. Tregs with an MHC class Ⅱ peptide-specific chimeric antigen receptor prevent autoimmune diabetes in mice[J]. J Clin Invest, 2023, 133(18): e168601. DOI: 10.1172/JCI168601.

[26] WANG S S, DU Y Y, ZHANG B Y, et al. Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient[J]. Cell, 2024, 187(22): 6152-6164.e18. DOI: 10.1016/j.cell.2024.09.004.

[27] MULLARD A. First-of-a-kind stem-cell therapies set for approval in Japan[J]. Nature, 2026, 651(8104): 13-14. DOI: 10.1038/d41586-026-00585-x.

[28] RUSSELL S, BENNETT J, WELLMAN J A, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2017, 390(10097): 849-860. DOI: 10.1016/S0140-6736(17)31868-8.

[29] JINEK M, CHYLINSKI K, FONFARA I, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity[J]. Science, 2012, 337(6096): 816-821. DOI: 10.1126/science.1225829.

[30] MEISEL R. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia[J]. N Engl J Med, 2021, 384(23): e91. DOI: 10.1056/NEJMc2103481.

[31] GILLMORE J D, GANE E, TAUBEL J, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis[J]. N Engl J Med, 2021, 385(6): 493-502. DOI: 10.1056/NEJMoa2107454.

[32] FINKEL R S, MERCURI E, DARRAS B T, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy[J]. N Engl J Med, 2017, 377(18): 1723-1732. DOI: 10.1056/NEJMoa1702752.

[33] ADAMS D, GONZALEZ-DUARTE A, O'RIORDAN W D, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis[J]. N Engl J Med, 2018, 379(1): 11-21. DOI: 10.1056/NEJMoa1716153.

[34] RAY K K, WRIGHT R S, KALLEND D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol[J]. N Engl J Med, 2020, 382(16): 1507-1519. DOI: 10.1056/nejmoa1912387.

[35] POLACK F P, THOMAS S J, KITCHIN N, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine[J]. N Engl J Med, 2020, 383(27): 2603-2615. DOI: 10.1056/nejmoa2034577.

[36] XU S J, LIANG D, WANG Q D, et al. In vivo genome editing of human haematopoietic stem cells for treatment of blood disorders using mRNA delivery[J]. Nat Biomed Eng, 2026, 10: 473-489. DOI: 10.1038/s41551-025-01480-y.

[37] WANG Q, XIAO Z X, ZHENG X, et al. In vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus[J]. N Engl J Med, 2025, 393(15): 1542-1544. DOI: 10.1056/nejmc2509522.

[38] CHEN A X Y, YAP K M, KIM J S, et al. Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery[J]. Nature, 2025, 644(8075): 241-251. DOI: 10.1038/s41586-025-09212-7.

基金资助

国家科技重大专项———四大慢病重大专项(2024ZD0537803)

临港国家实验室科研任务项目(LGL-2612-11)

国家自然科学基金(82501026)

中国博士后科学基金(BX20240497)

中国博士后科学基金(2025M774432)

重大疾病新药靶发现及新药创制全国重点实验室开放课题(SKLD2024M04)